Clinical trials: Non Alcoholic Fatty Liver Disease
Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
The purpose of this study is to directly characterize the pharmacokinetic (PK) profiles of MGL-3196 and its major metabolite (MGL-3623) following administration of multiple oral doses (QD x 6 days) in subjects with varying…
- Conditions
- Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
- Trial name
- NCT04643795
- Testing
- MGL-3196
- Where
- 3 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Epilepsy, Cardiovascular Disease
Impact of Ketogenic Diet on Lipoproteins in Refractory Epilepsy
The ketogenic diet is a non-pharmacological treatment prescribed especially for children and indicated in most specialized centers for patients with refractory epilepsy.
- Conditions
- Epilepsy, Cardiovascular Disease, Non-alcoholic Fatty Liver Disease, Quality of Life
- Trial name
- Ketonutri (NCT02644239)
- Testing
- ketogenic diet
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo
Chronic or Recovered Hepatitis B, Chronic or Recovered Hepatitis C
Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease
Background: The COVID-19 global pandemic killed more than 6 million people worldwide. Several vaccines have been developed against the virus that causes this disease.
- Conditions
- Chronic or Recovered Hepatitis B, Chronic or Recovered Hepatitis C, Chronic or Recovered Hepatitis D, NAFLD
- Trial name
- NCT05669677
- Where
- United States
- Volunteers
- 233 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatic Cirrhosis, Liver Fibrosis
A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis
This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and liver cirrhosis (liver damage…
- Conditions
- Hepatic Cirrhosis, Liver Fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis
- Trial name
- FALCON 2 (NCT03486912)
- Testing
- BMS-986036
- Where
- 91 sites in United States, Japan
- Volunteers
- 155 people
- Sponsor
- Bristol-Myers Squibb
Coronary Artery Calcification
Association Between Non-alcoholic Fatty Liver Disease (NAFLD) and Coronary Artery Calcification
Coronary artery disease are 8 times more prevalent in patients with NAFLD then the general population and are being considered the most common cause of death.
- Trial name
- NCT01158066
- Testing
- CT Cardiac
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Ziv Hospital
Liver Diseases
S.P.PRO LIVER POWDER is Used to Improve Liver and Metabolic Indexes in People With Non-alcoholic Fatty Liver Disease
With the Westernization of the diet and insufficient exercise, Taiwan's population of obesity, diabetes, and hyperlipidemia has increased in recent years, and the prevalence of the non-alcoholic fatty liver disease has gradually…
- Trial name
- NCT04718051
- Testing
- Shen Pu Yang Gan Wan
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taipei Medical University WanFang Hospital
NASH
Misoprostol for NASH
The aim of this randomised control trial is to evaluate the effect of Misoprostol in treating patients with NASH.
- Trial name
- NCT05804305
- Testing
- Misoprostol
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- Ziauddin University
Non Alcoholic Fatty Liver Disease
The Effect of Oral β- Glucan Supplement on Appetite and Insulin Resistance in Non Alcoholic Fatty Liver Disease
The Objective of This Study is Evaluating the Effect of oral β- glucan Supplement on Anthropometric Measurements, Appetite, Insulin Resistance, Liver echogenicity and Enzymes in Non Alcoholic Fatty Liver Patients Treating with…
- Trial name
- NCT02178839
- Testing
- β- glucan, Maltodextrin
- Where
- Iran
- Volunteers
- 48 people
- Sponsor
- Urmia University of Medical Sciences
Fatty Liver Disease
Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
To investigate the prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among adults in China
- Trial name
- MAFLD (NCT05421572)
- Testing
- Fibrotouch
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Liver Diseases, Liver Cirrhosis
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
The main objective of the study is to determine the diagnostic performances of an ultraportable diagnostic ultrasound system for the assessment of liver fibrosis severity in patients with NASH, and to compare them to other…
- Conditions
- Liver Diseases, Liver Cirrhosis, NASH - Nonalcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
- Trial name
- POCUS-NASH (NCT05120557)
- Testing
- Ultrasound liver assessment
- Volunteers
- 1,000 people
- Sponsor
- E-Scopics
Non-Alcoholic Fatty Liver Disease
Investigating Pathological Mechanisms in Non-alcoholic Fatty Liver Disease
To identify key characteristics of the tissue resident and peripherally circulating immune-phenotype in addition to blood markers, metabolic profile, faecal and oral microbiota in non-alcoholic fatty liver disease
- Trial name
- NCT04141592
- Testing
- Bariatric Surgery
- Where
- United Kingdom
- Volunteers
- 153 people
- Sponsor
- Queen Mary University of London
Non-Alcoholic Fatty Liver Disease
Cold-induced Brown Fat Activation and Hepatic Steatosis
In the recent years, research on brown adipose tissue (BAT) revealed that larger amounts as well as higher activity thereof are associated with a favourable metabolic phenotype.
- Trial name
- NCT03811236
- Testing
- Cold exposure
- Where
- Austria
- Volunteers
- 26 people
- Sponsor
- Medical University of Vienna
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease
Liver Stiffness And Steatosis Assessment In Women With Polycystic Ovary Syndrome Using Fibroscan
Polycystic Ovary Syndrome (PCOS) is a complex endocrine and metabolic disorder prevalent among women of reproductive age. It is closely associated with insulin resistance, obesity, and metabolic dysfunction, often leading to…
- Trial name
- NCT07027332
- Testing
- FibroScan® (Echosens, Paris, France)
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bezmialem Vakif University
Non Alcoholic Steatohepatitis
Coffee Consumption and NASH in the French Population.
The aim of our study is to evaluate the effect of coffee consumption on the risk of severe liver fibrosis in French patients with NASH.
- Trial name
- COCANASH (NCT03432377)
- Where
- 16 sites in France
- Volunteers
- 107 people
- Sponsor
- Versailles Hospital
Cardiovascular Diseases, Osteoporosis
Guangzhou Nutrition and Health Study (GNHS)
Purpose: The Guangzhou Nutrition and Health Study (GNHS) project aims to assess the determinants of metabolic disease in nutritional aspects, as well as other environmental and genetic factors, and explore possible mechanisms…
- Conditions
- Cardiovascular Diseases, Osteoporosis, Diabetes Mellitus, Type 2, Metabolic Syndrome
- Trial name
- GNHS (NCT03179657)
- Volunteers
- 5,118 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Non-alcoholic Fatty Liver Disease
Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)
This study will evaluate changes in liver fat content following multiple oral doses of MK-4074 and Pioglitazone Hydrochloride in adult males and females with fatty liver disease.
- Trial name
- NCT01431521
- Testing
- MK-4074 200 mg, Pioglitazone hydrochloride 30 mg
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Type 2, NAFLD
Effects of a Portfolio Diet on NAFLD in Type 2 Diabetic Patients
Patients with type 2 diabetes and non-alcoholic fatty liver disease will be enrolled. According to a parallel design, the participants will be randomized to a Portfolio diet or a monounsaturated fatty acid (MUFA)-rich diet (used…
- Trial name
- MEDEA (NCT03380416)
- Testing
- Portfolio Diet, MUFA Diet
- Where
- Italy
- Volunteers
- 49 people
- Sponsor
- Federico II University
Non-Alcoholic Fatty Liver Disease
Lysosomal Acid Lipase Activity in Nonalcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is a multifactorial disease affecting a quarter of the world population. Pathological accumulation of fat, into the hepatocytes, is the first hit and is due to altered hepatic and…
- Trial name
- NAFLD LAL (NCT05419765)
- Testing
- Peripheral blood withdrawn
- Where
- Italy
- Volunteers
- 316 people
- Sponsor
- University of Roma La Sapienza
Obesity, NASH - Nonalcoholic Steatohepatitis
Diagnostic Accuracy of the "LLIFT", a Novel Non-invasive Biomarker for the Diagnosis of Non Alcoholic Fatty Liver (NAFL) and SteatoHepatitis (NASH) in a Population With High Risk of Metabolic Syndrome"
The NAFLD is the first cause of liver disease worldwide. The severe form of NAFLD, the NASH progresses to cirrhosis and is responsible of liver mortality.
- Trial name
- LLIFT (NCT04616664)
- Where
- 7 sites in France
- Volunteers
- 158 people
- Sponsor
- University Hospital, Lille
Nonalcoholic Steatohepatitis (NASH), Fibrosis, Liver
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
This is a randomized, double-blind, placebo-controlled, parallel-dosing, multi-center study to evaluate the efficacy and safety of Rencofilstat as evidenced by histopathological improvements in fibrosis in adult NASH subjects…
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Fibrosis, Liver, NAFLD
- Trial name
- ASCEND (NCT05402371)
- Testing
- Rencofilstat
- Where
- 41 sites in United States, France and 1 more
- Volunteers
- 120 people
- Sponsor
- Hepion Pharmaceuticals, Inc.